VIA
VIR icon

Virtus Investment Advisers’s Vir Biotechnology VIR Stock Holding History

Virtus Investment Advisers’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$387K Sell
38,002
-2,757
-7% -$26.2K 0.09% 297
2026
Q1 		$365K Buy
40,759
+995
+3% +$7.93K 0.1% 253
2025
Q4 		$240K Buy
39,764
+17,966
+82% +$107K 0.07% 347
2025
Q3 		$124K Buy
21,798
+3,784
+21% +$19.3K 0.04% 403
2025
Q2 		$90.8K Sell
18,014
-4,079
-18% -$21.9K 0.03% 375
2025
Q1 		$143K Buy
+22,093
New +$196K 0.04% 347

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Virtus Investment Advisers's VIR Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Vir Biotechnology (VIR) stake by 6.8% in Q2 2026, selling an estimated $26.2K and leaving 38,002 shares worth $387K. The position accounts for 0.09% of the portfolio, ranked #297.

Virtus Investment Advisers first reported a position in VIR in Q1 2025 and has held it in 6 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Virtus Investment Advisers held 38,002 shares of Vir Biotechnology worth $387K as of Q2 2026.
  • Virtus Investment Advisers sold 2,757 Vir Biotechnology shares in Q2 2026, an estimated $26.2K.
  • Vir Biotechnology made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #297 holding.
  • Virtus Investment Advisers first reported a position in Vir Biotechnology in Q1 2025 and has held it in 6 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.